Actuate Therapeutics receives Nasdaq notice over its share price below $1
Actuate Therapeutics disclosed a Nasdaq notice over its share price below $1 and two compliance deadlines, as reported by TradingView, citing SEC filings.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Actuate Therapeutics has disclosed a notice from Nasdaq, as reported by TradingView on October 30, 2026. According to the exchange's October 28 letter, the company's stock closed under the $1.00 minimum bid price for 30 straight business days, which breaches the continued listing requirement under rule 5450(a)(1).
The deadline to restore compliance falls on April 26, 2027. The Nasdaq notice does not change how the shares trade in the near term. Separately, the company has until January 11, 2027 to fix a shortfall in its minimum market value of listed securities.
why it matters
For stocks trading below a dollar, such notices often signal pressure on the share price and liquidity, though the notice itself does not trigger immediate trading restrictions. Further disclosures on both deadlines will show whether the company can meet the requirements.
tags
instruments
sources
- Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard — TradingView, 30 October 2026 at 20:13 UTC
- Alset Disclosed Failure to Satisfy a Continued Listing Rule or Standard — TradingView, 30 October 2026 at 21:13 UTC
- Annovis Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard — TradingView, 30 October 2026 at 21:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗